P53- and mevalonate pathway–driven malignancies require Arf6 for metastasis and drug resistance

Ari Hashimoto(Hokkaido University), Hisataka Sabe(Hokkaido University)
The Journal of Cell Biology
April 4, 2016
Cited by 58


Related Papers